Our business model is to identify product opportunities in commercially and clinically relevant areas where our ElectroNanospray technology and expertise can contribute to improving drug performance. We develop drug product intermediate formulations, conduct preclinical proof-of-concept studies, secure IP protection for the product, and seek collaboration and out-licensing partners for these development products.